Welcome to Lab Test Consult

You can log in and post your comments

Share your knowledge and experience!

Member Login
Lost your password?

Dosing Begins for GOG US Cervical Cancer Study Evaluating ADXS-HPV

January 11, 2012


., (OTCBB: ADXS.OB – News), a leader in developing the next
generation of immunotherapies for cancer and infectious diseases,
announced at the OneMedForum in San Francisco that patient dosing has
begun in the Gynecologic Oncology Group (GOG) 67 patient Phase 2 study
evaluating Advaxis’ ADXS-HPV construct for the treatment of advanced
cervical cancer. The study is sponsored by the GOG with the majority of
funding from the National Cancer Institute.

The GOG study is in a patient population similar to the ongoing 110
patient study that Advaxis is conducting in India. Both studies will
assess safety and efficacy in cervical cancer patients who have not
responded to conventional cytotoxic treatment and whose cancer has
metastasized and resumed growth. Details about the GOG-sponsored study
can be found at ClinicalTrials.gov
Identifier NCT01266460.

“This study will complement our cervical cancer trial in India and, upon
completion of enrollment for both trials, result in a total of over 170
patients in our Phase 2 cervical cancer program,” commented Advaxis
Chairman CEO Tom Moore. “Enrollment for the study in India is about
80% complete. We will release additional data on January 25 at the World
Cancer Immunotherapy Congress in San Diego.”

About the Gynecologic Oncology Group (GOG)

The Gynecologic Oncology Group (GOG) is one of the National Cancer
Institute’s (NCI) funded cooperative cancer research groups. GOG is the
only group that focuses its research on women with pelvic malignancies,
such as cancer of the ovary, uterus, and cervix. It is a non-profit
organization with the purpose of promoting excellence in the quality and
integrity of clinical and basic scientific research in the field of
gynecologic malignancies. The Group is committed to maintaining the
highest standards in clinical trials development, execution, analysis,
and distribution of results. Additional information can be found at: www.gog.org.
Protocol information for the GOG-sponsored study can be found at ClinicalTrials.gov
Identifier NCT01266460.

January is Cervical Health Awareness Month

The United States Congress designated January as Cervical Health
Awareness Month to highlight issues related to cervical cancer, HPV
disease, and the importance of early detection. This month is dedicated
to bringing awareness to the personal stories of women and family
members/caregivers battling issues related to their persistent
HPV/pre-cancer and/or cervical cancer and to place an emphasis on the
importance of early detection, education, and the emotional issues
related to cervical cancer and HPV. For more information please visit: http://www.nccc-online.org/awareness.html

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next
generation of immunotherapies for cancer and infectious diseases.
Advaxis immunotherapies are based on a novel platform technology using
live, attenuated bacteria that are bio-engineered to secrete an
antigen/adjuvant fusion protein designed to redirect the powerful immune
response all human beings have to the bacterium to the cancer

Advaxis’ most advanced construct, ADXS-HPV, is being evaluated in 4
Phase 2 clinical trials for HPV-associated diseases: CIN 2/3 (US study,
Clinical Trials.gov Identifier NCT01116245), locally advanced cervical
cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460),
recurrent/refractory cervical cancer (India), and head neck cancer
(CRUK study) with over 150 patients receiving over 350 doses to date.
Over fifteen (15) distinct constructs are in various stages of
development, developed directly by the Company and through strategic
collaborations with recognized centers of excellence such as: the National
Cancer Institute
, Cancer
Research – UK
, the Wistar
, the University
of Pennsylvania
, the University
of British Columbia
, and others. For more information please visit: advaxis.com
| twitter
| LinkedIn

Forward-Looking Statements

This news release contains forward-looking statements, including,
but not limited to: statements as to the anticipated timing of clinical
studies and other business developments, statements as to the
development of new constructs, expectations as to the adequacy of our
cash balances to support our operations for specified periods of time
and as to the nature and level of cash expenditures, expectations as to
market opportunities, our ability to take advantage of those
opportunities, and the risk factors set forth from time to time in
Advaxis’ SEC filings, including but not limited to its report on Form
10-K for the fiscal year ended October 31, 2010, which is available at
The Company undertakes no obligation to publicly release the result of
any revision to these forward-looking statements that may be made to
reflect the events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events, except as required by law. You
are cautioned not to place undue reliance on any forward-looking

Article source: http://finance.yahoo.com/news/dosing-begins-gog-us-cervical-141500218.html


Related posts:

  1. HPV Test Spots Cervical Cancer Earlier Than Pap Smear: Study
  2. DIY cervical cancer test could save lives: study
  3. HOUSECALL: Women must take active role in detection of cervical cancer
  4. Doctors: Pap remains best test for cervical cancer
  5. Study: Routine prostate cancer testing does not save lives
  6. PSA Test for Prostate Cancer Doesn’t Save Lives: Study
  7. No extra birth defect risk after cancer treatment: study
  8. Pro-life advocates: Study shows link between breast cancer and abortion; cancer institute: no way
  9. Men More Likely to Skip Cancer Screenings: Study
  10. U.S. Blacks More Likely to Die of Colon Cancer Than Whites: Study


New post


March 2019
« Aug    


Recent comments

    Contact Sign In

    Email Marketing You Can Trust